Conjugate Vaccines Market by Type and Geography - Forecast and Analysis 2020-2024

コンジュゲートワクチンの世界市場:種類別、地域別

◆タイトル:Conjugate Vaccines Market by Type and Geography - Forecast and Analysis 2020-2024
◆商品コード:IRTNTR40714
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2019年12月10日
◆ページ数:151
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥277,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥333,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥444,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

本レポートは、コンジュゲートワクチンの市場実態を調査・分析し、エグゼクティブサマリー、レポートの範囲、市場状況、市場規模、ファイブフォース分析、種類別(多価コンジュゲートワクチン、一価コンジュゲートワクチン)分析、顧客状況、地域別状況、意思決定フレームワーク、市場の要因と課題、市場動向、企業状況、企業分析を掲載しています。
・エグゼクティブサマリー
・レポートの範囲
・市場状況
・市場規模
・ファイブフォース分析
・コンジュゲートワクチンの世界市場:種類別(多価コンジュゲートワクチン、一価コンジュゲートワクチン)
・顧客状況
・地域別状況
・意思決定フレームワーク
・市場の要因と課題
・市場動向
・企業状況
・企業分析

Global Conjugate Vaccines Market: About this market
Technavio’s conjugate vaccines market analysis considers sales from the multivalent conjugate vaccine and monovalent conjugate vaccine types. Our study also finds the sales of conjugate vaccines in Asia, Europe, North America, and ROW. In 2019, the multivalent conjugate vaccine segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the prevention of diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive diseases will play a significant role in the multivalent conjugate vaccine segment to maintain its market position. Also, our global conjugate vaccines market report looks at factors such as increased funding for vaccine development, awareness about immunization programs and access to vaccines, and approval and regulatory incentives for conjugated vaccines. However, high costs associated with vaccine research, development, and manufacturing, safety concerns associated with conjugate vaccines, and challenges in development and global implementation of conjugate vaccines hamper the growth of the conjugate vaccines industry over the forecast period.

Global Conjugate Vaccines Market: Overview
Increasing awareness about immunization programs and access to vaccines
Initiatives aimed at increasing the awareness about well recognized and successful public health immunization programs are promoting the overall vaccine coverage around the globe. For instance, World Pneumonia Day is celebrated every year on November 12 to lower the incidence of pneumonia and reduce the resultant mortality rate. Similarly, other programs are focusing on improving drug delivery and diagnostics to address the health issues in low and middle-income countries. Such initiatives targeted towards boosting access to vaccines will drive the demand for conjugate vaccines. Conjugate vaccines are developed to immunize against a single antigen or two or more strains of the same microorganism. Thus, the promotion of immunization programs will lead to the expansion of the global conjugate vaccines market at a CAGR of over 9% during the forecast period.
Increasing efforts for stockpiling of conjugate vaccines
Governments are putting efforts to store vaccines in bulk to combat future emergency outbreaks of infectious diseases. For instance, The United Nations Children’s Fund (UNICEF) works in collaboration with several public and private organizations to procure vaccines to combat future emergency outbreaks of infectious diseases. Furthermore, the International Coordinating Group (ICG) on Vaccine Provisions for Epidemic Meningitis Control also unites several public and private organizations to support emergency health programs and disease outbreak programs. The ongoing efforts in this area are expected to present significant growth opportunities for the existing vendors to meet the unmet demand for meningococcal conjugate vaccines, which will support the growth of the market during the forecast period.
For the detailed list of factors that will drive the global conjugate vaccines market during the forecast period 2020-2024, click here.

Competitive Landscape
With the presence of a few major players, the global conjugate vaccines market is concentrated. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading conjugate vaccines manufacturers, that include Aurobindo Pharma Ltd., GlaxoSmithKline Plc, Integrated Biotherapeutics Inc., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Pfenex Inc., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., and Sun Pharmaceutical Industries Ltd.
Also, the conjugate vaccines market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【資料の目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Parent market
• Market characteristics
• Value Chain Analysis
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2019
• Market Outlook
• Market size and forecast 2019-2024
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Multivalent conjugate vaccine – Market size and forecast 2019-2024
• Monovalent conjugate vaccine – Market size and forecast 2019-2024
• Market opportunity by type
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2019-2024
• Europe – Market size and forecast 2019-2024
• Asia – Market size and forecast 2019-2024
• ROW – Market size and forecast 2019-2024
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Increasing research activities for novel conjugate vaccine development
• Emergence of strategies to improve conjugate vaccine manufacturing
• Increasing efforts for stockpiling of conjugate vaccines
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Aurobindo Pharma Ltd.
• GlaxoSmithKline Plc
• Integrated Biotherapeutics Inc.
• Merck & Co. Inc.
• Mitsubishi Tanabe Pharma Corp.
• Pfenex Inc.
• Pfizer Inc.
• Sanofi
• Serum Institute of India Pvt. Ltd.
• Sun Pharmaceutical Industries Ltd.
PART 14: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO


Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Vendors: Key offerings
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2019
Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
Exhibit 10: Five forces analysis 2019
Exhibit 11: Five forces analysis 2024
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2019
Exhibit 18: Type – Market share 2019-2024 (%)
Exhibit 19: Comparison by type
Exhibit 20: Multivalent conjugate vaccine – Market size and forecast 2019-2024 ($ millions)
Exhibit 21: Multivalent conjugate vaccine – Year-over-year growth 2020-2024 (%)
Exhibit 22: Monovalent conjugate vaccine – Market size and forecast 2019-2024 ($ millions)
Exhibit 23: Monovalent conjugate vaccine – Year-over-year growth 2020-2024 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2019-2024 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America – Market size and forecast 2019-2024 ($ millions)
Exhibit 29: North America – Year-over-year growth 2020-2024 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe – Market size and forecast 2019-2024 ($ millions)
Exhibit 32: Europe – Year-over-year growth 2020-2024 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia – Market size and forecast 2019-2024 ($ millions)
Exhibit 35: Asia – Year-over-year growth 2020-2024 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW – Market size and forecast 2019-2024 ($ millions)
Exhibit 38: ROW – Year-over-year growth 2020-2024 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: Aurobindo Pharma Ltd. – Vendor overview
Exhibit 49: Aurobindo Pharma Ltd. – Business segments
Exhibit 50: Aurobindo Pharma Ltd. – Organizational developments
Exhibit 51: Aurobindo Pharma Ltd. – Geographic focus
Exhibit 52: Aurobindo Pharma Ltd. – Key offerings
Exhibit 53: Aurobindo Pharma Ltd. – Key customers
Exhibit 54: GlaxoSmithKline Plc – Vendor overview
Exhibit 55: GlaxoSmithKline Plc – Business segments
Exhibit 56: GlaxoSmithKline Plc – Organizational developments
Exhibit 57: GlaxoSmithKline Plc – Geographic focus
Exhibit 58: GlaxoSmithKline Plc – Segment focus
Exhibit 59: GlaxoSmithKline Plc – Key offerings
Exhibit 60: GlaxoSmithKline Plc – Key customers
Exhibit 61: Integrated Biotherapeutics Inc. – Vendor overview
Exhibit 62: Integrated Biotherapeutics Inc. – Business segments
Exhibit 63: Integrated Biotherapeutics Inc. – Key offerings
Exhibit 64: Integrated Biotherapeutics Inc. – Key customers
Exhibit 65: Merck & Co. Inc. – Vendor overview
Exhibit 66: Merck & Co. Inc. – Business segments
Exhibit 67: Merck & Co. Inc. – Organizational developments
Exhibit 68: Merck & Co. Inc. – Geographic focus
Exhibit 69: Merck & Co. Inc. – Segment focus
Exhibit 70: Merck & Co. Inc. – Key offerings
Exhibit 71: Merck & Co. Inc. – Key customers
Exhibit 72: Mitsubishi Tanabe Pharma Corp. – Vendor overview
Exhibit 73: Mitsubishi Tanabe Pharma Corp. – Business segments
Exhibit 74: Mitsubishi Tanabe Pharma Corp. – Organizational developments
Exhibit 75: Mitsubishi Tanabe Pharma Corp. – Geographic focus
Exhibit 76: Mitsubishi Tanabe Pharma Corp. – Key offerings
Exhibit 77: Mitsubishi Tanabe Pharma Corp. – Key customers
Exhibit 78: Pfenex Inc. – Vendor overview
Exhibit 79: Pfenex Inc. – Business segments
Exhibit 80: Pfenex Inc. – Organizational developments
Exhibit 81: Pfenex Inc. – Key offerings
Exhibit 82: Pfenex Inc. – Key customers
Exhibit 83: Pfizer Inc. – Vendor overview
Exhibit 84: Pfizer Inc. – Business segments
Exhibit 85: Pfizer Inc. – Organizational developments
Exhibit 86: Pfizer Inc. – Geographic focus
Exhibit 87: Pfizer Inc. – Segment focus
Exhibit 88: Pfizer Inc. – Key offerings
Exhibit 89: Pfizer Inc. – Key customers
Exhibit 90: Sanofi – Vendor overview
Exhibit 91: Sanofi – Business segments
Exhibit 92: Sanofi – Organizational developments
Exhibit 93: Sanofi – Geographic focus
Exhibit 94: Sanofi – Segment focus
Exhibit 95: Sanofi – Key offerings
Exhibit 96: Sanofi – Key customers
Exhibit 97: Serum Institute of India Pvt. Ltd. – Vendor overview
Exhibit 98: Serum Institute of India Pvt. Ltd. – Product segments
Exhibit 99: Serum Institute of India Pvt. Ltd. – Organizational developments
Exhibit 100: Serum Institute of India Pvt. Ltd. – Key offerings
Exhibit 101: Serum Institute of India Pvt. Ltd. – Key customers
Exhibit 102: Sun Pharmaceutical Industries Ltd. – Vendor overview
Exhibit 103: Sun Pharmaceutical Industries Ltd. – Business segments
Exhibit 104: Sun Pharmaceutical Industries Ltd. – Organizational developments
Exhibit 105: Sun Pharmaceutical Industries Ltd. – Geographic focus
Exhibit 106: Sun Pharmaceutical Industries Ltd. – Key offerings
Exhibit 107: Sun Pharmaceutical Industries Ltd. – Key customers
Exhibit 108: Validation techniques employed for market sizing
Exhibit 109: Definition of market positioning of vendors



【掲載企業】

Aurobindo Pharma Ltd., GlaxoSmithKline Plc, Integrated Biotherapeutics Inc., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Pfenex Inc., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., and Sun Pharmaceutical Industries Ltd.

★調査レポート[コンジュゲートワクチンの世界市場:種類別、地域別] (Conjugate Vaccines Market by Type and Geography - Forecast and Analysis 2020-2024 / IRTNTR40714)販売に関する免責事項
[コンジュゲートワクチンの世界市場:種類別、地域別] (Conjugate Vaccines Market by Type and Geography - Forecast and Analysis 2020-2024 / IRTNTR40714)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆